Format

Send to

Choose Destination
See comment in PubMed Commons below
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):197-203. doi: 10.1016/j.cytogfr.2010.02.005. Epub 2010 Mar 17.

Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme.

Author information

1
Division of Neurosurgery, Department of Surgery, Duke University Medical Center, Durham, NC 27710, USA.

Abstract

PVS-RIPO is a genetically recombinant, non-pathogenic poliovirus chimera with a tumor-specific conditional replication phenotype. Consisting of the genome of the live attenuated poliovirus type 1 (Sabin) vaccine with its cognate IRES element replaced with that of human rhinovirus type 2, PVS-RIPO displays an inability to translate its genome in untransformed neuronal cells, but effectively does so in cells originating from primary tumors in the central nervous system or other cancers. Hence, PVS-RIPO unleashes potent cytotoxic effects on infected cancer cells and produces sustained anti-tumoral responses in animal tumor models. PVS-RIPO presents a novel approach to the treatment of patients with glioblastoma multiforme, based on conditions favoring an unconventional viral translation initiation mechanism in cancerous cells. In this review we summarize advances in the understanding of major molecular determinants of PVS-RIPO oncolytic efficacy and safety and discuss their implications for upcoming clinical investigations.

PMID:
20299272
PMCID:
PMC2881183
DOI:
10.1016/j.cytogfr.2010.02.005
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center